Compare · DXCM vs RCEL
DXCM vs RCEL
Side-by-side comparison of DexCom Inc. (DXCM) and Avita Medical Inc. (RCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and RCEL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.67B, about 173.2x RCEL ($136.6M).
- Over the past year, DXCM is down 24.8% and RCEL is down 51.9% - DXCM leads by 27.1 points.
- RCEL has been more active in the news (11 items in the past 4 weeks vs 8 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 6 for RCEL).
- Company
- DexCom Inc.
- Avita Medical Inc.
- Price
- $61.33+3.02%
- $4.44+3.14%
- Market cap
- $23.67B
- $136.6M
- 1M return
- -1.65%
- +17.62%
- 1Y return
- -24.81%
- -51.95%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 8
- 11
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Avita Medical Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
Latest RCEL
- Avita Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- AVITA Medical Names Cary Vance as Chief Executive Officer
- AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
- AVITA Medical to Announce First Quarter 2026 Financial Results
- SEC Form DEF 14A filed by Avita Medical Inc.
- AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
- AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
- SEC Form EFFECT filed by Avita Medical Inc.
- SEC Form PRE 14A filed by Avita Medical Inc.
- AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness